Joseph Turner
Director/Board Member at Swarthmore College
Net worth: 37 040 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Keith Leonard | M | 62 | 14 years | |
| Jay Ramsinghani | M | - | 6 years | |
| Ayisha Jeter | F | - | 4 years | |
| Joseph Lyon | M | 46 | 12 years | |
| Sue-Jean Lin | F | 65 | 3 years | |
| Richard Barasch | M | 70 |
Swarthmore College
| - |
| Terrie Curran | F | 55 | 4 years | |
| Neha Krishnamohan | F | 37 | 2 years | |
| Ambrose Bailey | M | 60 | 9 years | |
| Halley Gilbert | F | 54 | 4 years | |
| Masaru Matsuda | M | 53 | 2 years | |
| Maria Hilado | F | 59 | 9 years | |
| Daniel Swisher | M | 61 | 9 years | |
| Max Barker | M | - |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | - |
| Eric Adler | M | - |
Swarthmore College
| - |
| Michael Costonis | M | 53 |
Swarthmore College
| - |
| Bruce Binkowitz | M | - | 3 years | |
| Ephriam Greenwall | M | - |
Swarthmore College
| - |
| Ephraim Greenwall | M | - |
Swarthmore College
| - |
| Rajvir Madan | M | - | 3 years | |
| Patrik Jonsson | M | 57 | 34 years | |
| Tyrone Dunston | M | - |
Swarthmore College
| - |
| Valerie Smith | F | 68 |
Swarthmore College
| 9 years |
| Tood Tucker | M | - | 4 years | |
| Amanda Sheldon | F | - | 3 years | |
| David Kabakoff | M | 76 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | 6 years |
| Patrick Burnett | M | 52 | 4 years | |
| Jere D. Fellmann | M | 72 | 12 years | |
| Paul I. Corddry | M | 87 |
Swarthmore College
| - |
| Corey Mulloy | M | 53 |
Swarthmore College
| 4 years |
| Chris Richard | M | 54 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | - |
| Fouad Azzam | M | 57 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | - |
| Joël Jean-Mairet | M | 52 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | 7 years |
| Peggy A. Seiden | F | - |
Swarthmore College
| 26 years |
| Gustavo Schwed | M | 62 |
Swarthmore College
| - |
| Cathy Polinsky | F | 47 |
Swarthmore College
| - |
| Graeme Currie | - | - |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | - |
| Vivek C. Varma | M | 58 |
Swarthmore College
| - |
| James C. Hormel | M | - |
Swarthmore College
| - |
| Jorge Ramentol Massana | M | - | 8 years | |
| Joan Fanés Trillo | M | - | 8 years | |
| Courtney Barton | F | 41 | 3 years | |
| Sergio Ferrer-Salat Serra di Migni | M | - | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Lechleiter | M | 70 | 38 years | |
| August Moretti | M | 73 | 7 years | |
| Stephen Hoffman | M | 70 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 years |
| Randall L. Tobias | M | - | 12 years | |
| Mark Oki | M | 55 | 9 years | |
| Nathaniel David | M | 56 | 11 years | |
| Bryce D. Carmine | M | 72 | 29 years | |
| Michael Grey | M | 71 |
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | 7 years |
| J. William Freytag | M | 72 |
Gilead Colorado, Inc.
 Gilead Colorado, Inc. Pharmaceuticals: MajorHealth Technology Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO. | 8 years |
| David Climie | M | - |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Hal Barron | M | 62 | 6 years | |
| Kenneth R. Lynn | M | 70 |
Cortech, Inc.
| 5 years |
| Anne Nobles | M | 67 | 22 years | |
| Frank M. Deane | M | 74 | 26 years | |
| Rolf K. Hoffmann | M | 64 | 17 years | |
| Amit Munshi | M | 56 | 5 years | |
| F. Ball | M | 68 | 2 years | |
| John Smither | M | 71 | 11 years | |
| Richard Pilnik | M | 67 | 25 years | |
| Keith L. Klein | M | 60 | 2 years | |
| John Archdeacon | M | - |
Centaur Pharmaceuticals, Inc.
Cortech, Inc.
| 7 years |
| Suzanne P. Welsh | F | 71 |
Swarthmore College
| 12 years |
| Michael Morneau | M | 58 |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | 2 years |
| François Kress | M | 57 | 5 years | |
| Diana McKenzie | F | 59 | 12 years | |
| Daniel J. Estes | M | 43 | 3 years | |
| Michael Harrington | M | 61 | 29 years | |
| Frederick C. Beddingfield | M | 59 | 2 years | |
| Alexander G. Asam | M | 58 | 1 years | |
| Camille Samuels | F | 52 | 10 years | |
| Gordon Ringold | M | 73 | 15 years | |
| J. Buchi | M | 69 | 3 years | |
| Hironori Hozoji | M | 63 | 4 years | |
| James Cornelius | M | 81 | 12 years | |
| William R. Rohn | M | 80 | 3 years | |
| Isaac Stein | M | 77 | 15 years | |
| Karen N. Horn | M | 80 | 29 years | |
| Robert Nelsen | M | 60 | 8 years | |
| J. Read | M | 73 | 12 years | |
| Gerry Proehl | M | 65 | - | |
| Daniel Bradbury | M | 62 | 7 years | |
| Deirdre Connelly | F | 63 | 26 years | |
| Robert L. Roe | M | 83 | 12 years | |
| Hollings Renton | M | 77 | 1 years | |
| Keith E. Brauer | M | 75 | 6 years | |
| Dennis Fenton | M | 72 | 9 years | |
| David Schnell | M | 64 | 8 years | |
| Jonathan Silverstein | M | 57 | 3 years | |
| Deepa Pakianathan | M | 59 | 12 years | |
| Michael Bristow | M | 79 |
Gilead Colorado, Inc.
Gilead Colorado, Inc. Pharmaceuticals: MajorHealth Technology Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO. | 10 years |
| Rowe Heather Armstrong | F | - | 1 years | |
| Andrew Dickinson | M | 54 |
Gilead Colorado, Inc.
Gilead Colorado, Inc. Pharmaceuticals: MajorHealth Technology Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO. | 2 years |
| Paul F. Banta | M | 63 | 8 years | |
| Subhas Gupta | M | - | - | |
| A. Jay Graf | M | - | 14 years | |
| Mohammed Khoso Baluch | M | 66 | 24 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.97% |
| Canada | 3 | 3.03% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph Turner
- Personal Network
